Rabies Monoclonal Antibody Market, Global Outlook and Forecast 2023-2030
Rabies Monoclonal Antibody Market, Global Outlook and Forecast 2023-2030
Anti-rabies virus monoclonal antibody is a passive immune preparation, which has the same or better neutralizing effect as rabies immunoglobulin. The development of anti-rabies virus monoclonal antibodies to replace traditional human immunoglobulin and immune antiserum products is an important direction of international research in this field in recent years. WHO also strongly recommends the use of monoclonal antibody combination preparations to replace rabies immunoglobulin to solve rabies The problem of insufficient supply of immunoglobulins.
This report contains market size and forecasts of Rabies Monoclonal Antibody in Global, including the following market information:
Global Rabies Monoclonal Antibody Market Size 2024-2030, ($ millions)
The global Rabies Monoclonal Antibody market is projected to reach US$ million by 2029.
We surveyed the Rabies Monoclonal Antibody companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Rabies Monoclonal Antibody Market, by Type, 2024-2030 ($ millions)
Global Rabies Monoclonal Antibody Market Segment Percentages, by Type
Category II Exposure
Category III Exposure
Global Rabies Monoclonal Antibody Market, by Application, 2024-2030 ($ millions)
Global Rabies Monoclonal Antibody Market Segment Percentages, by Application
Adult
Children
Global Rabies Monoclonal Antibody Market, By Region and Country, 2024-2030 ($ Millions)
Global Rabies Monoclonal Antibody Market Segment Percentages, by region and country
United States
Europe
Asia
China
Rest of World
Competitor Analysis
The report also provides analysis of leading market participants including:
Further, the report presents profiles of competitors in the market, key players include:
Serum Institute of India
NCPC
Crucell
Zydus
Synermore Biologics
